National Pension Service Sells 10,749 Shares of IDEXX Laboratories, Inc. $IDXX

National Pension Service trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 106,344 shares of the company’s stock after selling 10,749 shares during the quarter. National Pension Service’s holdings in IDEXX Laboratories were worth $71,945,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of IDXX. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $30,000. Greykasell Wealth Strategies Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $35,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $36,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $563.53 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98. The company has a market cap of $44.45 billion, a P/E ratio of 41.50, a P/E/G ratio of 3.27 and a beta of 1.58. The business has a fifty day simple moving average of $564.58 and a 200 day simple moving average of $637.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, BTIG Research dropped their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $751.00.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.